Biocon And Viatris Scoop EU Insulin Aspart Approval
Analyst Expects Biosimilar Penetration To Be ‘Slow And Minimal’
Executive Summary
Biocon and Viatris have landed their second biosimilar insulin approval in Europe, for a rival to Novo Nordisk’s NovoRapid (insulin aspart). Analyst reaction was lukewarm considering the “disappointing” launch of insulin glargine in Europe more than two years ago.